Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States

Pediatrics

Volumn 124, Issue SUPPL. 5, 2009, Pages

  Shen, Angela K ^a   Rodewald, Lance E ^b   Birkhead, Guthrie S ^c,d,e  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e National Vaccine Advisory Committee   (United States)

Author keywords

Financing; Immunization; Manufacturers; Vaccination; Vaccine

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGITIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADVISORY COMMITTEE; ARTICLE; CHILD; CHILD HEALTH CARE; DRUG COST; DRUG MANUFACTURE; FINANCIAL MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; IMMUNIZATION; INTERVIEW; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; REIMBURSEMENT; UNITED STATES; VACCINATION;

ADOLESCENT; ATTITUDE; CHILD; CHILD, PRESCHOOL; CONTRACT SERVICES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; FEMALE; FINANCING, GOVERNMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT; INSURANCE CARRIERS; MALE; MEDICALLY UNINSURED; PUBLIC SECTOR; REIMBURSEMENT MECHANISMS; UNITED STATES; VACCINATION; VACCINES;

EID: 71849110154     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-1542N     Document Type: Article

References (27)

1. DiMasi J, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151-185 (Pubitemid 36279392)
2. Douglas RG, Samant V. The vaccine industry. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. New York, NY: Saunders; 2008:37-44
3. Plotkin S. Why certain vaccines have been delayed or not developed at all. Health Aff (Millwood). 2005;24(3):631-634
4. Peter G, des Vignes-Kendrick M, Eickhoff TC, et al. Lessons learned from a review of the development of selected vaccines. Pediatrics. 1999;104(4):942-950
5. Klein JO, Myers MG. Vaccine shortages: why they occur and what needs to be done to strengthen vaccine supply. Pediatrics. 2006;117(6):2269-2275
6. Bondi MA, Harris JR, Atkins D, French ME, Umland B. Employer coverage of clinical preventive services in the United States. Am J Health Promot. 2006;20(3):214-222 (Pubitemid 43107684)
7. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. House and Senate Appropriations Committee revised report to Congress on the 317 Immunization Program. Available at: www.317coalition.org/documents/2009CDCImmunization.pdf. Accessed April 9, 2009
8. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years: United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;57(51):Q-1-Q-4
9. Centers for Disease Control and Prevention. CDC vaccine price list. Available at: www.cdc.gov/vaccines/programs/vfc/cdcvac-price-list.htm. Accessed February 2, 2009
10. Institute of Medicine. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press; 2003
11. Freed GL, Cowan AE, Clark SJ. Primary care physician perspectives on reimbursement for childhood immunizations. Pediatrics. 2008;122(6):1319-1324
12. Coleman MS, Lindley MC, Ekong J, Rodewald L. Net financial gain or loss from vaccination in pediatric medical practices. Pediatrics. 2009;124(suppl 5):S472-S491
13. Freed GL, Cowan AE, Gregory S, Clark SJ. Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics. 2008;122(6):1325-1331
14. National Vaccine Advisory Committee. National Vaccine Advisory Committee Vaccine Financing Stakeholders Meeting. April 29-30, 2008. Available at: www.hhs.gov/nvpo/nvac/agendaSH200804.html. Accessed March 23, 2009
15. Lindley MC, Orenstein WA, Shen AK, Rodewald LE, Birkhead GS. Assuring Vaccination of Children and Adolescents Without Financial Barriers: Recommendations From the National Vaccine Advisory Committee (NVAC), U.S. Department of Health and Human Services. Washington, DC: National Vaccine Advisory Committee Vaccine Financing Working Group; 2009. Available at: www.hhs.gov/nvpo/nvac/NVACVFWGReport.pdf. Accessed March 23, 2009
16. Vaccines for Children Access Act of 2008, S 2465, 110th Cong, 1st Sess (2007)
17. Vaccines for Children Access Act of 2008, HR 4990, 110th Cong, 2nd Sess (2008)
18. Freed GL, Katz SL. The comprehensive Childhood Immunization Act of 1993: toward a more rational approach. N Engl J Med. 1993;329(26):1957-1960
19. Salinsky E, Werble C. The Vaccine Industry: Does It Need a Shot in the Arm? Washington, DC: National Health Policy Forum, George Washington University; 2006. Available at: www.nhpf.org/library/details.cfm/2506. Accessed April 14, 2009
20. Hinman AR, Gellin BG; National Vaccine Advisory Committee. Institute of Medicine report on financing vaccines in the 21st century: National Vaccine Advisory Committee/National Vaccine Program Office follow up. Available at: www.hhs.gov/nvpo/nvac/NVAC-IOM100604.htm. Accessed April 14, 2009
21. Advisory Committee on Immunization Practices. ACIP Charter, April 2008-May 2010. Available at: www.cdc.gov/vaccines/recs/ACIP/charter.htm. Accessed April 14, 2009
22. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298(18):2155-2163
23. Coleman M, Sangrujee N, Zhou F, Chu S. Factors affecting U.S. manufacturers' decisions to produce vaccines. Health Aff (Millwood). 2005;24(3):635-642
24. Valentini G, Zavanella L. The consignment stock of inventories: industrial case and performance analysis. Int J Prod Econ. 2003;81-82(11):215- 224 (Pubitemid 35385360)
25. Merck. Dose replacement program for Gardasil. Available at: www.drp4gardasil.com/Site/Home.aspx. Accessed December 17, 2008
26. US Food and Drug Administration. Vaccines licensed for immunization and distribution in the US with supporting documents. Available at: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093830.htm. Accessed March 19, 2009
27. Lindley MC, Shen AK, Orenstein WA, Rodewald LE, Birkhead GS. Financing the delivery of vaccines to children and adolescents: challenges to the current system. Pediatrics. 2009;124(suppl 5):S548-S557